1107 studies found for:    Ovarian Cancer: Clinical Trials
Show Display Options
Rank Status Study
21 Recruiting Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence
Condition: First Recurrence of Ovarian Cancer
Interventions: Procedure: Secondary citoreduction;   Procedure: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
22 Recruiting Autologous OC-DC Vaccine in Ovarian Cancer
Conditions: Chemotherapy;   Tumor;   Ovarian Cancer
Intervention: Biological: OCDC
23 Completed
Has Results
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: Pemetrexed - Phase 1;   Drug: Carboplatin - Phase 1;   Drug: Pemetrexed - Phase 2;   Drug: Carboplatin - Phase 2
24 Recruiting The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
Condition: Ovarian Cancer (Epithelial)
Intervention: Radiation: involved-field radiation therapy
25 Recruiting Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Condition: Ovarian Cancer
Intervention: Drug: IMAB027
26 Terminated
Has Results
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Biological: Abagovomab;   Biological: Placebo
27 Completed
Has Results
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Ontak
28 Completed A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer
Intervention: Biological: DCVac-L
29 Terminated
Has Results
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a
30 Recruiting A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Conditions: Breast Cancer;   Melanoma;   Non-small Cell Lung Cancer;   Ovarian Cancer;   Sarcoma
Intervention: Biological: ID-LV305
31 Recruiting A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
Conditions: Melanoma;   Ovarian Cancer;   Sarcoma;   Non-small Cell Lung Cancer;   Breast Cancer
Intervention: Biological: IDC-G305
32 Recruiting Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: chemotherapy with doxorubicin and cisplatin
33 Active, not recruiting Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Procedure: Tumor collection
34 Completed
Has Results
Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Bendamustine HCL
35 Recruiting A Clinical Trial in Patients With BRCA Defective Tumours
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Drug: 6-Mercaptopurine;   Drug: Methotrexate
36 Terminated Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Doxil (Pegylated Liposomal Doxorubicin);   Drug: BIBF 1120
37 Recruiting Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pimasertib once daily;   Drug: Pimasertib placebo;   Drug: SAR245409 placebo;   Drug: SAR245409;   Drug: Pimasertib twice daily
38 Terminated Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Condition: Recurrent Epithelial Ovarian Cancer
Intervention: Biological: DC-006 vaccine
39 Recruiting Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer
Conditions: Primary Malignant Neoplasm of Ovary;   FIGO Stages II to IV
Interventions: Drug: Decitabine (DTC Arm);   Drug: Paclitaxel and Carboplatin (TC Arm)
40 Recruiting Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years